Cambridge, MA, United States of America

Dirk Hockemeyer

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Sangamo Therapeutics, Inc.. Active years: 2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dirk Hockemeyer. Retrieved from https://idiyas.com/inventor/dirk-hockemeyer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank


 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Dirk Hockemeyer

Introduction: Dirk Hockemeyer is a renowned inventor based in Cambridge, MA, known for his groundbreaking contributions to the field of science and technology.

Latest Patents: Dirk Hockemeyer holds several patents in the areas of biotechnology, genetic engineering, and genome editing, showcasing his continuous commitment to innovation.

Career Highlights: With a background in molecular biology and genetics, Dirk Hockemeyer has made significant strides in developing novel techniques for gene editing and cellular reprogramming, revolutionizing the way we approach genetic diseases and biotechnological advancements.

Collaborations: Throughout his career, Dirk Hockemeyer has collaborated with leading research institutions, biotech companies, and universities worldwide, fostering a culture of innovation and knowledge exchange in the scientific community.

Conclusion: Dirk Hockemeyer's passion for pushing the boundaries of science and technology has solidified his reputation as a pioneering inventor, with his work continuing to inspire future generations of innovators.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…